HomeCompareKYKOF vs FCPT

KYKOF vs FCPT: Dividend Comparison 2026

KYKOF yields 3.62% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KYKOF wins by $30.8K in total portfolio value· pulled ahead in Year 6
10 years
KYKOF
KYKOF
● Live price
3.62%
Share price
$12.42
Annual div
$0.45
5Y div CAGR
34.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.9K
Annual income
$20,662.92
Full KYKOF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — KYKOF vs FCPT

📍 KYKOF pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKYKOFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KYKOF + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KYKOF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KYKOF
Annual income on $10K today (after 15% tax)
$307.97/yr
After 10yr DRIP, annual income (after tax)
$17,563.48/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, KYKOF beats the other by $12,654.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KYKOF + FCPT for your $10,000?

KYKOF: 50%FCPT: 50%
100% FCPT50/50100% KYKOF
Portfolio after 10yr
$64.5K
Annual income
$13,219.10/yr
Blended yield
20.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

KYKOF
No analyst data
Altman Z
4.5
Piotroski
6/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KYKOF buys
0
FCPT buys
0
No recent congressional trades found for KYKOF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKYKOFFCPT
Forward yield3.62%6.05%
Annual dividend / share$0.45$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR34.2%15.8%
Portfolio after 10y$79.9K$49.1K
Annual income after 10y$20,662.92$5,775.28
Total dividends collected$53.3K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: KYKOF vs FCPT ($10,000, DRIP)

YearKYKOF PortfolioKYKOF Income/yrFCPT PortfolioFCPT Income/yrGap
1$11,186$486.23$11,401$700.92$215.00FCPT
2$12,651$682.18$13,064$864.84$413.00FCPT
3$14,505$967.66$15,051$1,072.48$546.00FCPT
4$16,911$1,391.42$17,442$1,337.22$531.00FCPT
5$20,130$2,034.69$20,340$1,677.08$210.00FCPT
6← crossover$24,577$3,037.59$23,880$2,116.57+$697.00KYKOF
7$30,948$4,651.34$28,241$2,689.36+$2.7KKYKOF
8$40,461$7,346.19$33,660$3,442.07+$6.8KKYKOF
9$55,339$12,045.62$40,456$4,439.95+$14.9KKYKOF
10$79,875$20,662.92$49,063$5,775.28+$30.8KKYKOF

KYKOF vs FCPT: Complete Analysis 2026

KYKOFStock

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Full KYKOF Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this KYKOF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KYKOF vs SCHDKYKOF vs JEPIKYKOF vs OKYKOF vs KOKYKOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.